Skip to main content

Table 1 Characteristics of included studies

From: Efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV infected children and adolescents: a systematic review and meta-analysis

Studies Brennan 2014 [29] Musiime 2014 [28] PENTA 2002 [31, 32] Technau 2014 [14, 15]
Type of study Prospective cohort study Randomised controlled trial Randomised controlled trial Retrospective cohort study
Age range 5 to 14 years 1 month to 13 years 3 months to 16 years 4 to 129 months
Countries included South Africa Uganda Zambia Belgium, Brazil, France, Germany, Ireland, Italy, Portugal, Spain and UK South Africa
Period of enrollment April 2009 to March 2011 May 2010 to September 2013 January 1998 to July 2000 August 1998 to April 2013
Sample size (n) 557 365 130 9543
Intervention Abacavir, Lamivudine and Efavirenz Abacavir, Lamivudine and NNRTI Abacavir and Lamivudine ± Nelfinavir Abacavir, Lamivudine and Lopinavir/ritonavir or Efavirenz
Comparators Stavudine, Lamivudine and Efavirenz Zidovudine, Lamivudine and NNRTI Abacavir and Zidovudine ± Nelfinavir Stavudine, Lamivudine and Lopinavir/ritonavir or Efavirenz
Stavudine, Lamivudine and NNRTI Lamivudine and Stavudine ± Nelfinavir
Length of follow up Up to 24 months Up to 96 weeks Up to 5 years Up to 48 weeks
Funding sources United States Agency for International Development (USAID) Medical Research Council UK European Commission, Medical Research Council, the Istituto Superiore di Sanità, Comunidad Autonoma de, Glaxo-Wellcome and Agouron National Institutes of Health